All News

pain.jpg

A Potential Biomarker for Chronic Fatigue Syndrome Patients

d Jack Cush, MD

Myalgic encephalomyelitis/chronic fatigue syndrome affects at least 2 million people in the United States and bears tremendous overlap with fibromyalgia - both being difficult to diagnosis because the symptom complex is often unrecognized and these conditions have no biomarker test. 

Read Article
handcropped.RA_.jpg

Upadacitinib Superior to Adalimumab in Methotrexate Refractory RA

d Jack Cush, MD

Upadacitinib, a JAK1-selective inhibitor, was studied head to head against adalimumab and placebo in rheumatoid arthritis after an inadequate response to methotrexate, and shown to be superior to ADA and PBO in ACR20 and DAS remission level responses.

Read Article
hospital-13-1518181.jpg

Cardiovascular Disease Increased in Hospitalized Lupus Patients

d Jack Cush, MD

Systemic lupus erythematosus (SLE) patients who are hospitalized have an increased prevalence of atherosclerotic cardiovascular disease (ASCVD) and its individual phenotypes of coronary artery disease (CAD), peripheral artery disease (PAD), and cerebrovascular disease. 

Read Article
infusion.biologic.jpg

Rituximab Safety Concerns when Used in anti-TNF Refractory RA

d Jack Cush, MD

The SUNSTONE study evaluated the long‐term safety of rituximab in rheumatoid arthritis (RA) previously exposed to ≥1 anti–tumor necrosis factor inhibitors (TNFi) and showed a stable, but high, rate of serious infections, opportunistic infections and an overall higher mortality rate.

Read Article
renal.genes_.jpg

Rituximab Superior to Cyclosporine for Membranous Nephropathy

d Jack Cush, MD

The NEJM has reported that rituximab (RTX) and cyclosporine (CYA) was noninferior to cyclosporine in inducing complete or partial remission of proteinuria at 12 months and was superior in maintaining proteinuria remission up to 24 months. 

Read Article
RN.podcast.resized.jpg

RheumNow Podcast – Boiling Hot MAS (7.12.19)

d Jack Cush, MD

Dr. Jack Cush reviews this week's news and journal reports featured on RheumNow.com. PsA v. non-PsA pregnancies, Still's disease, lupus, nutritional supplements and dietary interventions, use of cannabis, tanezumab in OA, CBD oils and more.

Read Article
exhausted.jpg (keep)

NIH Conference Review of Chronic Fatigue Syndrome

d Jack Cush, MD

The current issue of JAMA reviews recent advances on chronic fatigue syndrome, also known as myalgic encephalomyelitis/(ME/CFS), based on a 2-day conference held at the NIH in an April 2019.

The NIH 2-day conference reviewed recent progress and new research in several areas described below.

Read Article
Women in the OTIS Pregnancy Project (657 RA, 170 JIA vs 564 without autoimmune dz) - preterm delivery (PTD) was increased in RA & JIA (RR 2.09 & 1.81) vs control; maternal activity was assoc w/ PTD (ARR 1.58 & 1.52), steroids had a 2-5X risk of PTD https://t.co/bWIHz0s1PV

Links:

Dr. John Cush RheumNow ( View Tweet)

10 question UK survey on the use of HCQ in 989 patients (71% SLE; 12% UCTD/MCTD, 5.2% skin lupus, 11.5% RA, SS, etc). Results: 56% never had HCQ side effects; 23% had AE that improved; 12% had AE currently & 8.6% stopped HCQ for AE. https://t.co/iqJl0eEPTg

Links:

Dr. John Cush RheumNow ( View Tweet)

Its been 30-40 years since the "House of God" by Samuel Shem changed your medical thinking, if not humor. Check out Dr. Len Calabrese's recollections and call to join his summer book club and add some commentary!! https://t.co/L8wiGpWk42

Links:

Dr. John Cush RheumNow ( View Tweet)

A review of 376 FDA advisory panels between 2008-15, finds that 22% of FDA’s final actions were discordant with an advisory panels recommendations (moreso w/ safety panels). Of these, 3/4 lead to more restrictive actions and 1/4 less restrictive decisions https://t.co/AK7KbwN2l5

Links:

Dr. John Cush RheumNow ( View Tweet)

Analysis of 149 OA and 203 RA pts from Rush Univ Rheum Clinic showed the same disease burden (by RAPID3) betw OA & A at initial visits, but after 6 mos. RAPID3 was more improved in RA patients than OA patients (P < 0.001). https://t.co/fNQ2ncJScI

Links:

Dr. John Cush RheumNow ( View Tweet)

Analysis #osteoarthritis clinical trials placebo response ratio (PRR) as the placebo to treatment effect size ratio. PRR was best for walking time/distance (0.30, 95% CI 0.16 to 0.43) and worst for PRO pain (0.44, 95% CI 0.23 to 0.65) https://t.co/4VorQdSIV2

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast is up! Discussing MAS, CBD, CCP in PsA, Cost savings w/ LLDAS, lupus pregnancy and no go on NGF. View here>> https://t.co/zUclX3ISIs or listen on iTunes or SoundCloud>> https://t.co/DVw7Trrh5r

Links:

Dr. John Cush RheumNow ( View Tweet)

ER study from 2015-17 shows that among 456 #gout patients, 28.3%) received opioid at discharge; 80% of these were new. Average dose was 38mg morphine equivalent for a median of 8 days - more likely w/ polyarticular gout, hx diabetes & hx prior opioids https://t.co/xf2jD1i4hg

Links:

Dr. John Cush RheumNow ( View Tweet)

Upadacitinib versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate:- Arthritis & Rheumatology - second Jak to beat the gold standard!

Peter Nash drpnash ( View Tweet)

Do biologics work in relapsing polychondritis? French cohort of 41 pts use 105 biologics (TNFi=60; TCZ 17; anakinra 15; RTX 7; ABA6). While 63% resp in 1st 6 mos (on pred!), a complete response rate was 19.0%. Steroid sparing variable, high infx rates. https://t.co/Ff9KULlKVD

Links:

Dr. John Cush RheumNow ( View Tweet)

Swedish registry comparison of 541 PsA 40944 non-PsA pregnancies between 1997-2014, shows PsA pregnancies had increased risks for preterm birth (adj OR 1.63) and caesarean deliveries (OR 1.47), but no increased risks for pre-eclampsia, stillbirth https://t.co/L5GcNVbjgQ

Links:

Dr. John Cush RheumNow ( View Tweet)

Analysis of 14 studies &3291 Psoriatic arthritis patients shows the overall frequency of anti-CCP antibodies=9.8%. In PsA, CCP+ was associated with increased risks of polyarthritis (OR 4.4), bone erosion (2.8), and dactylitis (1.98), but not of enthesitis. https://t.co/hM11ZaskfV

Links:

Dr. John Cush RheumNow ( View Tweet)

Study of 182 hospitalized adult-onset Still's disease patients shows predictive factors for developing macrophage activation syndrome to include: 1. Splenomegaly (OR 5.745), 2. pericarditis (OR 6.5), and 3. ferritin >2000 (OR 4.7). https://t.co/oNsaCL6O92

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×